AdvanTIG-204

Completed

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Beigene Study ID info

AdvanTIG-204

ClinicalTrials.gov ID info

China Drug Trials ID info

CTR20211531

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents